AIDS vaccine researchers find promise
Recent data from clinical trials and shared lessons on recruitment and retention of volunteers highlight annual AIDS vaccines meeting
At the closing session of the AIDS Vaccine 2005 meeting in Montreal researchers summarized the state of the field and outlined the possibilities and problems that scientists, ethicists, and policy makers will face in the coming year. Many obstacles remain to the development of an effective AIDS vaccine, but during this year's annual conference the researchers who gathered received a promising report on the field. After four days of presentations that highlighted the advancements regarding clinical trials, the development of novel vaccine vectors, and the strategies for recruiting and educating trial volunteers, the speakers summarizing the meeting struck an optimistic tone.
One of these speakers, Lawrence Corey of the HIV Vaccine Trials Network (HVTN), predicted that the next year would bring substantial data on vaccines that induce cell-mediated immunity, the major focus of many of the current candidates in clinical trials. He also emphasized the importance of researchers working with and gaining the support of affected communities, as their involvement will continue to be critical. And as the annual meeting heads for European soil—in 2006 it will take place in Amsterdam—the research community began discussions about some of the remaining ethical dilemmas surrounding the design of clinical trials, including the need to evaluate AIDS vaccines in adolescent volunteers.
Clinical results
The Vaccine Research Center (VRC) at the US National Institutes of Health has tested a series of DNA vaccines developed in partnership with the biotechnology company Vical in Phase I clinical trials. Volunteers in one of these trials, VRC 004, received a DNA-based vaccine containing copies of four HIV genes from multiple subtypes, including those that are most prevalent in Africa and parts of Asia. These volunteers were later enrolled into trial VRC 009 where they received a second inoculation, known as a boost, with a different candidate that used an adenovirus as a vector to deliver HIV fragments to the immune system. The adenovirus vaccine was developed in partnership with the company GenVec. The natural form of this adenovirus vector can cause respiratory infections, including the common cold, but neither the DNA nor the adenovirus candidate used in this trial can cause HIV infection.
Barney Graham of the VRC presented the impressive results of VRC 009 in Montreal. Researchers observed that after receiving both vaccine components volunteers had a 10-20 times stronger antibody response than was induced by the DNA candidate alone. Graham also reported that cellular immune responses (CD8+ T cells) after boosting were comparable to those seen in people who are HIV infected but do not progress to AIDS within the average time-span, a group known as long term nonprogressors.
Because the VRC 009 trial enrolled volunteers from a previous trial there was a longer than normal period between the prime and boost inoculations. Graham speculated that this 2-year gap could be partially responsible for the strong results. "The long boosting interval probably does play a role in the improved immune response," Graham said at the meeting. He did acknowledge that this represents an impractical vaccination schedule, but said that these results argued for further testing of this approach with a more typical vaccination schedule.
This additional testing is now in progress and the VRC and HVTN just recently started enrolling 480 volunteers for a Phase II trial of this DNA/Ad5 combination vaccine to assess both its safety and immunogenicity (see VRC starts Phase II vaccine trial).
Promising news was also reported from another adenovirus-based vaccine developed by Merck. The company recently decided to increase enrollment in its Phase IIb 'test of concept' trial with the MRKAd5 candidate and Robin Isaacs of Merck presented the rationale for this decision at the conference (see Merck and HVTN expand Phase IIb trial). He also reported that approximately 1,200 volunteers have received the Ad5 candidate so far in all clinical trials and that the only side-effects observed are injection site reactions and fever after initial dosing. Results of this Phase IIb study are not expected until 2008. In the meantime Merck continues to look at other strains or serotypes of adenovirus, including Ad6, in order to broaden the immunogenicity of the vaccine and find what he refers to as the "ultimate" adenovirus-based vector.
As promise of the adenovirus-based vaccines continues to grow, others continue the search for novel viral vectors. The pharmaceutical company Wyeth has been working on the vesicular stomatitis virus (VSV) as a potential vector for several years. This virus has proven a potent delivery system for other diseases in laboratory and animal experiments.
At the conference Stephen Udem, vice president of viral vaccine research at Wyeth, presented much of the company's work on preparing these vectors for Phase I clinical trials. This work involved improving the safety of the vector while retaining its immunogenicity. Udem says the approach is "well regarded" by the US Food and Drug Administration and he predicts the VSV-based AIDS vaccine candidate could be in clinical trials within a year. The agency is currently in the process of reviewing the company's application to begin Phase I trials. "It's a remarkably effective agent," he says, and although he is continually surprised by the ability of HIV to escape the immune system, he is equally impressed by VSV as a vector.
Learning from experience
Another important focus of the AIDS vaccine meeting was the need to continue optimizing the design of vaccine trials, including ways to include more women volunteers. Several presentations in Montreal highlighted the experiences of researchers at trial sites, bringing to light some of the progress and problems in enrolling volunteers for ongoing trials or cohort studies.
Stephen Mawa of Makerere University and the Walter Reed Project in Kampala, Uganda presented on the experience of recruiting for a Phase I trial in 2004 with the VRC's DNA candidate (VRC 009). The trial site staff conducted more than 20 informative seminars for both community leaders and the general public—each attended by as many as 100 people—as well as using newspaper and radio advertisements to recruit potential volunteers. In total the site directly interacted with more than 4,000 people and although several hundred women were screened, only a few were enrolled.
Despite these extensive outreach efforts the majority of volunteers reported hearing about the study from friends. Mawa emphasized the need to engage in continuous AIDS vaccine advocacy and education since "word of mouth" will likely be an important recruitment tool in the future.
Sanjay Mehendale of the National AIDS Research Institute in Pune, India, where the country's first AIDS vaccine trial began earlier this year, presented more encouraging news on recruiting women for this Phase I vaccine trial. Preparations included sensitizing the trial staff about the need to recruit women, conducting meetings with local women's groups, as well as training the staff on gender-related issues that could affect participation. The IAVI-sponsored Phase I study enrolled 11 male and 9 female volunteers to receive either the low- or medium-level doses of the adeno-associated virus based vaccine called tgAAC09.
But getting this many female volunteers was not easy. To enroll just 9 women the site staff had to screen five times that number, illustrating that significant screening resources may be necessary if investigators are to recruit a balanced number of women in larger Phase II or III clinical trials in this country.
In preparation for such trials Projet San Francisco (PSF), a research group founded in Rwanda in 1986 by Susan Allen of Emory University, has been working extensively with African couples, including discordant couples where one partner is HIV infected and the other is uninfected. The PSF sites have been successful at bringing women into clinics for HIV counseling and testing and possible enrollment in a vaccine trial (see Primer on Understanding Couples Voluntary Counseling and Testing) and now represent the world's largest cohorts of HIV serodiscordant couples.
More than 20,000 couples have been screened at one of PSF's sites in Kigali, Rwanda over the past 3 years, 950 of whom have been identified as serodiscordant, according to a presentation by Erin Shutes who works at this site. The retention rates for these couples cohorts are around 90% through one year, offering a unique opportunity for investigators to reach potential female volunteers for vaccine trials. The researchers in Kigali are now preparing for a Phase I vaccine trial that will commence later this year pending final regulatory approval (see VRC starts Phase II vaccine trial).
Beyond the strategies for recruiting female volunteers, researchers within the AIDS vaccine community are also starting to consider evaluating promising candidates in adolescent volunteers. The inclusion of adolescents in AIDS vaccine trials brings up several ethical questions including informed consent, and will be an important issue for debate and discussion in the coming years. The Montreal meeting provided merely the background for what will be a thorny issue in AIDS vaccine research, but as Glenda Gray of the University of Witswatersand reminded researchers, "HIV prevalence among adolescents in South Africa is horrific and excluding them from efficacy trials is a big mistake."